<DOC>
	<DOCNO>NCT01611857</DOCNO>
	<brief_summary>This study Phase I/II trial Tivantinib plus FOLFOX treatment patient advance solid tumor . In Phase I Maximum Tolerated Dose ( MTD ) determine ; Phase II patient first-line metastatic GE cancer treat MTD . It hypothesize response rate ( RR ) improve 45 % least 65 % regimen .</brief_summary>
	<brief_title>Phase I/II Trial Tivantinib With FOLFOX Treatment Advanced Solid Tumors Previously Untreated Metastatic Adenocarcinoma Distal Esophagus , Gastroesophageal Junction Stomach</brief_title>
	<detailed_description>This Phase I , open-label , non-randomized , dose-escalation study Phase II portion plan upon reach Maximum Tolerated Dose recommend Phase II dose ( RP2D ) . Phase I : The first cycle Phase I portion trial consider Dose Limiting Toxicity evaluation period . Patients advance solid tumor treat Tivantinib Days 1 14 FOLFOX Day 1 . Following evaluation Dose Limiting Toxicities , dose escalated/reduced accord protocol 3 6 patient treat per dose level Maximum Tolerated Dose determine .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Life expectancy ≥12 week . Karnofsky performance status ≥70 % Patients must measurable disease per RECIST Version 1.1 . Adequate hematologic function define : Absolute neutrophil count ( ANC ) ≥1500/μL Hemoglobin ( Hgb ) ≥9 g/dL ( 5.6 mmol/L ) Platelets ≥100,000/uL Adequate liver function define : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST &lt; 2.5 x institutional upper limit normal ( ULN ) ≤5.0 x institutional ULN patient liver metastasis . Total bilirubin within normal limit ( WNL ) ( ≤1.5 x institutional ULN patient liver metastasis ; total bilirubin ≤3.0 x ULN direct bilirubin within normal limit patient well document Gilbert Syndrome ) . Serum creatinine &lt; 1.5 X ULN calculate 24hour creatinine clearance &gt; 40 mL/min . Patients coumadin international normalize ratio ( INR ) value within therapeutic range ( i.e. , 2 3 x ULN ) . Patients stable , chronic dos coumadin eligible . PHASE I ONLY •Patients must histologically confirm solid tumor malignancy metastatic unresectable standard therapy would include FOLFOX standard curative palliative measure exist longer effective . PHASE II ONLY Histologic documentation adenocarcinoma esophagus , GE junction , stomach . Metastatic GE cancer document radiologic study surgical evidence metastatic disease . No prior chemotherapy metastatic disease . Previous combined modality therapy locally advanced disease allow complete ≥6 month prior recurrence ( acceptable chemotherapy drug include 5FU , capecitabine , cisplatin , carboplatin , paclitaxel , oxaliplatin , docetaxel ) . Prior radiation therapy allow . At least 4 week must elapse completion radiation therapy sign toxicity must resolve . Prior adjuvant chemotherapy allow complete ≥6 month prior documentation metastatic disease . Patients known central nervous system ( CNS ) metastases may enrol , provide metastasis undergone treatment , patient asymptomatic , patient require antiepileptic drug steroid treatment CNS metastasis . Patients poorly control clinically significant atherosclerotic vascular disease include New York Heart Association Grade 3 great congestive heart failure ; unstable angina ; myocardial infarction , cardiovascular accident , transient ischemic accident , angioplasty , cardiac vascular stenting past 6 month ; ventricular arrhythmia require medication . Patients previously diagnose symptomatic bradycardia ineligible . Medical history prolong QT syndrome ( &gt; 450 m ) . Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit safety compliance study requirement . History hypersensitivity active inactive excipients component treatment ( 5FU , leucovorin , oxaliplatin , Tivantinib ) , know dipyrimidine dehydrogenase deficiency . Patients evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) . Significant vascular disease ( e.g. , aortic aneurysm require surgical repair , recent peripheral arterial thrombosis ) ≤6 month prior Day 1 treatment . Any known positive test human immunodeficiency virus , hepatitis C virus acute chronic hepatitis B infection . Mental condition would prevent patient comprehension nature , risk associate , study . Use nonapproved investigational agent ≤28 day 5 halflives prior administration first dose study drug , whichever short . Patients may receive investigational anticancer treatment participate study . Impairment gastrointestinal function gastrointestinal disease may significantly alter drug absorption ( e.g . active inflammatory bowel disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome ) . Inability swallow whole capsule . PHASE I ONLY •Patients radiation therapy , hormonal therapy , biologic therapy , investigational agent , chemotherapy cancer within 28 day 5 halflives chemotherapy biologic/targeted agent , whichever short , prior Day 1 study . PHASE II ONLY •Past current history neoplasm entry diagnosis exception treat nonmelanoma skin cancer carcinoma situ cervix , cancer cure local therapy alone disease free survival ≥5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>First-Line Metastatic GE cancer</keyword>
	<keyword>c-Met Inhibitor</keyword>
	<keyword>Tivantinib</keyword>
	<keyword>FOLFOX</keyword>
</DOC>